Allo-SCT in children with high-risk leukemia using unmanipulated grafts from alternative donors

Bone Marrow Transplantation

Volumn 42, Issue SUPPL. 2, 2008, Pages

  Sedlacek, P ^a   Mejstrikova, E ^a   Formankova, R ^a   Keslova, P ^a   Dobrovolna, M ^b   Vrana, M ^b   Stary, J ^a  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^b INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOSPORIN A; FOLINIC ACID; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER RISK; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; DONOR SELECTION; FATALITY; FOLLOW UP; HIGH RISK PATIENT; HLA MATCHING; HUMAN; INCIDENCE; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; REVIEW; SINGLE DRUG DOSE; SURVIVAL RATE; TREATMENT RESPONSE; WHOLE BODY RADIATION;

ACUTE DISEASE; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; DISEASE-FREE SURVIVAL; DONOR SELECTION; EUROPE; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; LEUKEMIA; LIVING DONORS; MALE; RECURRENCE; RISK FACTORS; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS;

EID: 55749110283     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.277     Document Type: Review

References (14)

1. Miano M, Labopin M, Hartmann O, Angelucci E, Cornish J, Gluckman E et al. Haematopoietic stem cell transplantation trends in children over the last three decades: A survey by the paediatric diseases working party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2007; 39: 89-99.
2. Klingebiel T, Handgretinger R, Lang P, Bader P, Niethammer D. Haploidentical transplantation for acute lymphoblastic leukemia in childhood. Blood Rev 2004; 18: 181-192.
3. Lang P, Greil J, Bader P, Handgretinger R, Klingebiel T, Schumm M et al. Long-term outcome after haploidentical stem cell transplantation in children. Blood Cells Mol Dis 2004; 33: 281-287.
4. Dey BR, Spitzer TR. Current status of haploidentical stem cell transplantation. Br J Haematol 2006; 135: 423-437.
5. Beck JF, Klingebiel T, Kreyenberg H, Schaudt A, Wolle W, Niethammer D et al. Relapse of childhood ALL, AML and MDS after allogeneic stem cell transplantation can be prevented by donor lymphocyte infusion in a critical stage of increasing mixed chimerism. Klin Padiatr 2002; 214: 201-205.
6. Sanchez J, Serrano J, Gomez P, Martinez F, Martin C, Madero L et al Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukaemia after allogeneic transplantation. Br J Haematol 2002; 116: 686-694.
7. Yoshimi A, Bader P, Matthes-Martin S, Stary J, Sedlacek P, Duffner U et al. Donor leukocyte infusion after hematopoietic stem cell transplantation in patients with juvenile myelomonocytic leukemia. Leukemia 2005; 19: 971-977.
8. Petersdorf EW. Risk assessment in haematopoietic stem cell transplantation: Histocompatibility. Best Pract Res Clin Haematol 2007; 20: 155-170.
9. Arcese W, Rocha V, Labopin M, Sanz G, Iori AP, de Lima M et al. Unrelated cord blood transplants in adults with hematologic malignancies. Haematologica 2006; 91: 223-230.
10. Wall DA, Carter SL, Kernan NA, Kapoor N, Kamani NR, Brochstein JA et al. Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: The Cord Blood Transplantation study (COBLT) experience. Biol Blood Marrow Transplant 2005; 11: 637-646.
11. Parkman R, Cohen G, Carter SL, Weinberg KI, Masinsin B, Guinan E et al. Successful immune reconstitution decreases leukemic relapse and improves survival in recipients of unrelated cord blood transplantation. Biol Blood Marrow Transplant 2006; 12: 919-927.
12. Barker JN. Who should get cord blood transplants? Biol Blood Marrow Transplant 2007; 13 (Suppl 1): 78-82.
13. Teshima T, Matsuo K, Matsue K, Kawano F, Taniguchi S, Hara M et al Impact of human leucocyte antigen mismatch on graft-versus-host disease and graft failure after reduced intensity conditioning allogeneic haematopoietic stem cell transplantation from related donors. Br J Haematol 2005; 130: 575-587.
14. Sramkova L, Muzikova K, Fronkova E, Krejci O, Sedlacek P, Formankova R et al. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2007; 48: 93-100.